INTRODUCTION
The International Berlin-Frankfurt-Münster Study Group (I-BFM-SG) comprises national study groups from more than 30 countries worldwide that collaborate in working committees to address important aspects of clinical and basic research in pediatric leukemia and lymphoma. Over the last 20 years, the BFM group conducted several highly successful clinical trials for childhood acute lymphoblastic leukemia (ALL) by using chemotherapy schedules based on the original BFM backbone. 1 Modifications of essentially all elements of therapy have been evaluated in randomized trials conducted by the most experienced European cooperative groups. [1] [2] [3] The progressive broadening of the I-BFM-SG to include new national groups with limited resources and less experience with complex and intensive chemotherapy regimens dictated the need for a study tailored to local conditions. On the basis of the pioneering findings of the BFM group on measurement of early response to therapy (ie, prednisone response [PR] in peripheral blood on day 8, and percentage of bone marrow [BM] blasts on day 15), all patients could be stratified in risk groups by widely accessible methods. 4, 5 minimal residual disease (MRD) provides a powerful tool for evaluating early treatment response in ALL. [6] [7] [8] The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) and BFM groups have shown that the use of PCR-MRD levels in weeks 5 and 12 provides a risk stratification strategy which, in most cases, overrides those based on traditional presenting features. [9] [10] [11] Yet this method is expensive and time-consuming, and it requires exquisite skills, thus limiting its use on an international scale. Therefore, the I-BFM-SG explored the feasibility of a stratification approach that was based on a combination of morphologic evaluation of PR on day 8 and BM blasts on days 15 and 33. This concept drove the design of the ALL IC-BFM 2002 trial to be conducted in countries with inadequate skills and resources for PCRbased MRD monitoring. The experience and know-how of the BFM group gleaned over 25 years coupled with available results of seminal North American trials 12 on the role of length and strength of postinduction intensification in National Cancer Institute (NCI) standardrisk (SR) and NCI high-risk (HR) ALL with rapid early response (RER) and slow early response to treatment helped generate a trial that explored the prognostic impact of a similar philosophy applied on the background of a traditional BFM backbone. We report treatment results of this trial involving 5,060 children from three continents.
PATIENTS AND METHODS

Patients
Experience with BFM-based chemotherapy, data management, randomization, and achievement of overall event-free survival (EFS) of more than 65% in recent years were all required for participation. Informed consent had to be obtained from each patient's guardians per the Helsinki Declaration, and the trial had to be approved according to national laws. Already established national groups participated in the study. Single centers were allowed to participate only if they managed at least 30 new patients with ALL per year to prevent selection bias; however, that introduced additional bias by excluding smaller centers. Only one large center in Moscow fulfilled this criterion along with the other requirements.
From November 1, 2002 , to November 15, 2007, a total of 5,060 evaluable patients younger than age 18 years with newly diagnosed non-B-cell ALL were enrolled onto the trial. It was recommended that infants younger than age by group according to previous experience with one of the two HR strategies in trials AIEOP-ALL 95 and ALL-BFM 95. Shaded boxes depict experimental arms of delayed intensification. 6-MP, mercaptopurine; BM, bone marrow; Dx, diagnosis; d, day; HR-1, HR experimental group; HR-1Ј, consolidation block HR-1Ј; HR-2Ј, consolidation block HR-2Ј; HR-3Ј, consolidation block HR-3Ј; HR-2A, HR control arm (AIEOP option); HR-2B, HR control arm (BFM option); II, III, protocol designations; IR-1, IR control group; IR-2, IR experimental group; IT, intrathecal; NR, nonresponder; PRED-PR, prednisone poor response; R, randomization; SR-1, SR control group; SR-2, SR experimental group; wk, week; wks, weeks. 1 year be enrolled onto a baby protocol, 13 which was pursued by the overwhelming majority of countries. Patients were treated in 130 centers in Argentina (n ϭ 1,270), Chile (n ϭ 558), Croatia (n ϭ 122), Cuba (n ϭ 151), Czech Republic (n ϭ 291), Hong Kong (n ϭ 155), Hungary (n ϭ 259), Israel (n ϭ 292), Poland (n ϭ 908), Serbia (n ϭ 266), Slovakia (n ϭ 137), Slovenia (n ϭ 36), Ukraine (n ϭ 421), Uruguay (n ϭ 96), and Moscow (n ϭ 98). The median follow-up was 4.9 years (range, 0 to 8 years). Twenty-four patients were lost to follow-up 1.0 to 7.9 years from diagnosis.
Diagnosis
ALL was diagnosed if at least 25% lymphoblasts were present in BM. Immunophenotyping was performed according to European Group for the Immunological Characterization of Leukemias (EGIL) criteria.
14 Karyotyping and molecular genetics (fluorescent in situ hybridization [FISH] , reverse transcriptase PCR) to investigate BCR-ABL and mixed lineage leukemia (MLL)-AF4 were mandatory. 15, 16 Central review on a national basis of all morphologic, standard flow cytometric, and molecular genetics results was required. Criteria for CNS involvement at presentation (and relapse) are specified in the Data Supplement. Patients were registered at the national data management office within 24 to 72 hours of diagnosis.
Response and Relapse Criteria
PR was determined by absolute blast count in peripheral blood on day 8, after 7 days of prednisone and one dose of intrathecal methotrexate (MTX) on day 1. Prednisone poor response (PPR) was defined as Ն 1 ϫ 10 9 /L blasts, and prednisone good response (PGR) was defined as less than 1 ϫ 10 9 /L blasts. 4 BM response to induction therapy was evaluated by morphology on days 15 and 33. Complete remission (CR) was defined as less than 5% blasts in a regenerating marrow on day 33 and no extramedullary disease. Failure to achieve CR by day 33 was not considered an event and was only triaged to HR. Resistance to therapy (nonresponse) was defined as no CR by the start of the third consolidation HR block. BM relapse was defined as reappearance of Ն 25% lymphoblasts in BM. Combined relapses meant recurrence in both BM and extramedullary site(s).
Stratification
Patients were stratified into three risk groups: (1) SR defined as PGR, age Ն 1 year to younger than 6 years, initial WBC less than 20 ϫ 10 9 /L, and M1 (Ͻ 5% blasts) or M2 (Ն 5% to Ͻ 25% blasts) marrow on day 15, and M1 marrow on day 33 (all criteria must be fulfilled); (2) intermediate risk (IR), defined as PGR, age younger than 1 year or age 6 years or older, Protocol II was given once in arms SR-1 and IR-1 as the only delayed intensification element, twice in arm HR-2A with one 4-week interim maintenance therapy in between, and once in arm HR-2B after completing a series of three HR blocks. In arm HR-2B, a series of the three HR blocks was given, first in consolidation (uniformly for all HR patients), and then as part of delayed intensification therapy (ie, six HR blocks were delivered in total). m Interim maintenance therapy started 1 week after the end of the intensive therapy element and finished 1 week before the next one. n Dose was adjusted according to WBC (target, 2,000 to 3,000/L). o Maintenance therapy started 2 weeks after the end of intensive therapy and was given until 104 weeks from diagnosis.
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www.jco.org and/or WBC Ն 20 ϫ 10 9 /L and M1 or M2 marrow on day 15 and M1 marrow on day 33, or SR criteria but M3 (Ն 25% blasts) marrow on day 15 and M1 marrow on day 33; or (3) HR, defined as at least one of the following: PPR, IR and M3 marrow on day 15, M2 or M3 marrow on day 33, t(9;22) (BCR-ABL), or t(4;11) (MLL-AF4).
Treatment and Toxicity
The treatment outline is depicted in Fig 1. Details of chemotherapy are provided in Table 1 , and the cumulative drug doses and length of all arms of delayed intensification (DI) are provided in the Data Supplement. In SR patients with B-cell precursor ALL (BCP-ALL), two doses of daunorubicin were prescribed in induction compared with four doses in all others. In consolidation, high-dose methotrexate was administered at 5 g/m 2 for SR/IR T-cell ALL (T-ALL) and at 2 g/m 2 for SR/IR BCP-ALL. 17,18 Consolidation for HR patients consisted of three intensive polychemotherapy blocks. Immediately on consolidation, patients were randomly allocated 1:1 to the experimental or control arm of DI stratified by risk group and country by using randomization lists generated by the study statistician with randomization blocks of size four. DI started 2 weeks thereafter. In SR, protocol III was repeated twice 12 weeks apart in the experimental arm (SR-2), although a single protocol II was given in the control arm (SR-1). In IR, protocol III was given three times 6 weeks apart in the experimental arm (IR-2), and a single protocol II was given in the control arm (IR-1). In HR, the experimental arm (HR-1), identical with that in IR, was tested against either protocol II given twice 6 weeks apart, as in AIEOP-ALL 95, 19 (HR-2A), or three HR blocks plus one protocol II, similar to ALL-BFM 95, 5 (HR-2B). The choice of the HR control arm was up to each national group according to its own experience.
Only T-ALL and HR patients age Ն 1 year received prophylactic cranial radiotherapy (12 Gy). Therapeutic cranial radiotherapy was reserved for patients with initial CNS involvement and given at an age-adjusted dosage: nil for infants younger than 1 year, 12 Gy for children age 1 to younger than 2 years, and 18 Gy for children age Ն 2 years.
Allogeneic hematopoietic stem-cell transplantation (HSCT) from matched sibling donor (MSD) was recommended for very-high-risk (VHR) patients defined as no CR by day 33; HR plus M3 on day 15; Philadelphia chromosome-positive ALL; PPR plus any of T-ALL, proB-ALL (very early CD10 Ϫ BCP-ALL), WBC more than 100 ϫ 10 9 /L, or t(4;11) (MLL-AF4). Toxicity was graded by modified Common Terminology Criteria for Adverse Events (CTCAE) v2.0 (Data Supplement).
Statistical Analysis
EFS and survival were calculated from date of diagnosis to date of first event, which for EFS was resistance, relapse, death, or second malignant ʈAcute myeloid leukemia (eight), lymphoma (six), non-Hodgkin lymphoma (five), Hodgkin lymphoma (one), myelodysplastic syndrome (two), histiocytic sarcoma (two), histiocytosis/Langerhans-cell histiocytosis (two), bone sarcoma (two), glioblastoma (one), malignant melanoma (one), and unknown (two). Six additional SMNs developed after relapse and relapse treatment.
neoplasm (SMN), and for survival, death as a result of any cause. If no event occurred, the observation time was censored at last follow-up. The main end point of the randomized questions was disease-free survival (DFS), defined as time from date of random assignment to first event (death in CR, relapse, SMN) or last follow-up. EFS/DFS and survival curves were estimated according to Kaplan-Meier 20 with SE from Greenwood 21 and compared by twotailed log-rank test.
22,23 Mantel-Byar modified life-table analysis was used to compare EFS of VHR patients managed by HSCT versus chemotherapy only. 24 Cumulative incidence curves for events were estimated by adjusting for competing risks 25 and were compared by Gray test. 26 Follow-up was updated as of November 15, 2010 . The trial was supervised by an independent data safety and monitoring committee. Statistical analysis was performed by using SAS-PC, v9.1 (SAS Institute, Cary, NC).
RESULTS
Of the 5,197 enrolled patients, 137 were not eligible for the following reasons: inclusion criteria not fulfilled (n ϭ 30), significant pretreatment (n ϭ 51), ALL was an SMN or there was another major disease prohibiting protocol treatment (n ϭ 22), and lack of essential diagnostic data (n ϭ 34). Eventually, 5,060 patients were eligible and evaluable. Patient characteristics and treatment results for the total evaluable population and by risk group are summarized in Table 2 .
EFS and Survival
For the 5,060 evaluable patients, the 5-year EFS (Ϯ SE) and survival probabilities were 74% (Ϯ 1%) and 82% (Ϯ 1%), respectively. The corresponding estimates were 81% (Ϯ 1%) and 90% (Ϯ 1%) for the SR group (n ϭ 1,564), 75% (Ϯ 1%) and 83% (Ϯ 1%) for the IR group (n ϭ 2,650), and 55% (Ϯ 2%) and 62% (Ϯ 2%) for the HR group (n ϭ 846; P Ͻ .001 for all; Fig 2) .
Events
Remission failures. CR was achieved in 4,920 patients (97.2%), but treatment failed for 140 children who died during induction (n ϭ 109; of these, 48 died within the first 2 weeks) or who had resistant disease. A total of 255 patients (5.3%) died in CR as a result of treatment-related events.
Relapses. The 5-year cumulative incidence of relapse (CIR) was 19% (Ϯ Ͻ 0.1%), with 1.9% (Ϯ Ͻ 0.1%) for isolated and 1.6% (Ϯ Ͻ 0.1%) for combined CNS relapse (Table 3) .
Treatment Results According to BM Stratification on Day 15
Seventy patients (4.4%) were shifted from SR to IR because of M3 BM on day 15. Their EFS was 60% (Ϯ 7%), significantly (P Ͻ .001) lower than the 83% (Ϯ 1%) EFS for patients with M1 BM on day 15 (n ϭ 1,159), and the 77% (Ϯ 2%) EFS for those with M2 BM on day 15 (n ϭ 374); it was also lower than that of IR patients with M1/M2 BM on day 15 (76% Ϯ 1%). Similarly, the 135 patients at IR (5.1%) upgraded to HR because of M3 BM on day 15 had EFS of 49% (Ϯ 5%), significantly worse than the 76% (Ϯ 1%) of IR patients with M1/M2 BM on day 15 (P Ͻ .001), and no better than that of HR patients treated with chemotherapy alone (Appendix Fig A1, online only) .
Randomization of DI
The 5-year DFS estimates were equivalent for the randomized treatments by intent-to-treat analysis ( Figs 3A-C) , the difference (control minus experimental) being 2% (95% CI, Ϫ5% to 2%) for SR, Ϫ2% (95% CI, Ϫ5% to 2%) for IR, and 2% (95% CI, Ϫ7% to 10%) for HR. Both HR control arms were merged and compared against the experimental arm, because the small numbers in either option precluded meaningful separate analysis.
All regimens of DI were well tolerated overall. The incidence of grade 3 to 4 nonhematologic toxicities by type of DI is listed in Table 4 . The experimental therapy was associated with more hepatotoxicity in SR and more infectious morbidity and transaminitis in IR, although more stomatitis occurred on HR control blocks.
HSCT in First CR
Of the 846 HR patients, 530 (62.6%) were eligible for HSCT from MSD in the first CR (CR1). Indeed, 131 (15.5%) were allografted in CR1 4 to 18 months (median, 7 months) from diagnosis. For patients who stayed in remission at least 6 months, the EFS was 63% (Ϯ 5%) for the HSCT group (n ϭ 106) versus 59% (Ϯ 3%) for the chemotherapy-only group (n ϭ 326; P ϭ .49). The outcome was also comparable between subgroups of VHR patients (Appendix Fig A2, online only; Data Supplement). HSCT was associated with a significantly higher cumulative incidence of therapy-related mortality (TRM; 18% v 9%; P ϭ .02), but with a trend for lower incidence of relapse (18% v 29%; P ϭ .09) compared with chemotherapy.
DISCUSSION
The main result of this large, intercontinental study is that at 5 years, 70% of patients remained disease free, with 80% alive, in a setting largely different from that of the most organized cooperative groups or single institutions. Undoubtedly, the collaborative effort entailed a major improvement in the ability to handle contemporary, intensive, and effective chemotherapy regimen for childhood ALL worldwide. The low proportion of missing data and the 78% randomization rate also attest to this progress.
Over the last two decades, the world's leading leukemia groups have achieved 5-year survival rates of approximately 90%, with 2% to 3% deaths as a result of toxicity in childhood ALL. 10, 11, 27 A major concern with BFM-type chemotherapy in the hands of less experienced groups with limited resources was the potential risk of excessive TRM. Indeed, we observed a 5% rate of death in CR, ranging from 3% in SR to 13% in HR patients. The incidence of death in CR was significantly higher in children age Ն 10 years versus younger children (9% v 4%; P Ͻ .001), in girls versus boys (6% v 5%; P ϭ .04), and in T-ALL versus BCP-ALL (8% v 5%; P Ͻ .001).
The CIR (19% overall; 3.5% CNS) is comparable to that observed in ALL-BFM 95 5 and AIEOP-ALL 95, 18 from which this trial was derived. A large proportion of patients (26.5%) received cranial irradiation. We confirmed AIEOP experience that 2 g/m 2 MTX is adequate to prevent CNS leukemia in non-HR BCP-ALL, provided intrathecal MTX is given during maintenance. 18 Whether 5 g/m 2 MTX could further reduce relapse risk in IR BCP-ALL remains unsolved, as evidenced by comparable BM and CNS relapses in ALL-BFM 95 5 and in our trial. Despite the high TRM (13.4%), our HR patients achieved 62% 5-year survival resulting from a relatively low relapse rate (25.2%), which compares favorably with ALL-BFM 90 (51.0% at 6 years; TRM, 5.8%), 17 ALL-BFM 95 (38.6% at 6 years; TRM, 8.7%), 5 and AIEOP-ALL 95 (33.4% at 5 years; TRM, 5.8%).
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Given the comparable backbone chemotherapy strategy among these studies, analysis of the few modifications may be informative: the improvement against ALL-BFM 90 could be attributed to introduction of protocol II in DI; better leukemia control in ALL IC-BFM 2002 and AIEOP-ALL 95, compared with ALL-BFM 95, may be ascribed to the postinduction protocol I/phase 2. 28 However, these differences should be judged with caution, also in view of the different follow-up times reported.
Evaluation of the prognostic impact of shifting SR and IR slow responders to a higher risk category is hampered by lack of head-tohead comparison, since this was a stratification criterion, not a randomized question. The difference in EFS of IR patients with M1/M2 BM on day 15 treated within IR and those with M3 treated within HR was 27% in favor of the former. Similarly, IR patients from ALL-BFM 95 stratified by BM status on day 15 identically who were all treated within IR had 5-year EFS of 83% (Ϯ 1%) versus 56% (Ϯ 6%), respectively, again for a 27% difference (M. Schrappe, personal communication, November 15, 2012) . This suggests no benefit from switching to HR strategy in the context of these BFM trials.
Protocol III was used in previous BFM trials. 1 In this study, oral interim maintenance therapy was interposed between protocol III repeats in DI. One randomized question per risk group was put forth to explore the prognostic impact of different types of DI. In SR, the rationale was to intensify treatment with nonmyelosuppressive drugs, avoiding undue complications. In IR, the cumulative doses of all drugs were increased in the hope of improving disease control. In HR, a longer split but less intensive schedule was tested. DFS, the study's primary end point, was no different between the randomized arms by intent-to-treat or by per-protocol analysis (the latter not shown). More extended intensification in the frame of a heavy BFM backbone also meant some discomfort for the patients and families because of the higher burden of longer intensive chemotherapy. This suggests that after long-lasting BFM-type intensive chemotherapy, more is not necessarily better in this phase of treatment for patients with RER. 29 Indeed, a second DI course added no benefit in the Children's Cancer Group (CCG) -1991 study for NCI-SR BCP-ALL with RER, 30 and the CCG-1961 study has shown that stronger but not longer postinduction intensification improved outcome in NCI-HR ALL with RER. 31 By contrast, for most patients with NCI-HR ALL and slow early response, augmented postinduction chemotherapy resulted in excellent outcome.
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The contribution of HSCT should be interpreted judiciously. The Mantel-Byar technique handles HSCT properly as a timedependent covariate. However, it does not compare predefined cohorts 24, 33 and cannot adjust for all sources of bias, including many confounders in this trial's setting. Unfortunately, reduction of relapses was offset by 18% TRM. Interestingly, the outcome after HSCT from MSD (n ϭ 87; EFS, 65.1%) was comparable to that of transplantations from matched unrelated donors (n ϭ 35; EFS, 63.6%). In any case, decreasing TRM to less than 10% is imperative.
EFS and survival for Ph-positive ALL were 47% (Ϯ 4%), and 57% (Ϯ 4%), respectively. Imatinib used in addition to chemotherapy in 21% of cases, not in accordance with protocol, might have partially contributed to these results, better compared with the preimatinib era.
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Treatment results varied widely among the participating countries. CR rates ranged from 90.7% to 100%, induction deaths from 0% to 6%, CR deaths from 1.3% to 8.6%, 5-year CIR rates from 11.2% to 24.4%, and 5-year EFS rates from 65.3% to 83.9%. Countries having a higher death rate in CR also faced higher relapse rates. Many participating national groups achieved results comparable to those recently reported by major international groups. Conversely, different levels of care between individual centers and the impossibility of referring difficult cases to more experienced centers played a role in certain countries. In addition, nonadherence to maintenance treatment because of worse socioeconomic conditions might partially explain the higher incidence of relapses in some countries. 36 In conclusion, ALL IC-BFM 2002 represents a model for wide, international collaboration in pediatric oncology. Starting from the consolidated experience of AIEOP and BFM groups, the design of this study allowed the achievement of remarkable results in treatment of the most frequent pediatric cancer in an extremely heterogeneous environment by a huge community with limited resources. The study was based on inexpensive, widely accessible stratification criteria (ie, early response to treatment measured by universally affordable methods). We consider the 74% 5-year EFS with 82% survival a great success achieved in an unselected group of countries, the majority of which have improved their treatment results in ALL. [37] [38] [39] [40] [41] [42] [43] [44] [45] 
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